Principal Scientist Gemma Keegan, part of our Formulation and Process Innovation team, has shared her expertise about drug delivery in the November edition of Pharmaceutical Technology magazine. Alongside two other industry experts, Gemma talks about the main drivers for alternative drug delivery formulation, promising approaches, formulation challenges, and the regulatory pathways.
Gemma also spoke about some of the potential beneficiaries: “Alternative drug delivery approaches may benefit therapies that need to overcome significant barriers resulting from the disease itself. For example, in cystic fibrosis, the overproduction of mucus … and treatments that specifically target cancerous cells within the lung.
“Selection of an inhaled drug delivery approach over more invasive options, such as by injection, may be preferred by some patients. Examples include severe asthmatics requiring antibody therapy or Parkinson’s patients receiving treatment for “off” periods.”
You can read the November edition of Pharmaceutical Technology magazine here.